AllSci News
Arcturus and CSL Seqirus terminate sa-mRNA vaccine partnership
San Diego-based Arcturus Therapeutics (Nasdaq: ARCT) has terminated its self-amplifying mRNA collaboration with CSL Seqirus through a settlement agreement,...
BioMarin drops BMN 401 following unsuccessful pivotal trial
BioMarin Discontinues BMN 401 Across All Indications After Pivotal ENPP1 Trial Fails Co-Primary Endpoints
Shape and Rett Syndrome Research Trust advance AI-designed RNA editor for R168X mutation
Seattle-based Shape Therapeutics and the Rett Syndrome Research Trust (RSRT) announced a partnership to advance SHP-401, an investigational RNA editing gene...
Tarsus secures USD 125m to fund Alkeus acquisition and expand eye care pipeline
Irvine, California-based Tarsus Pharmaceuticals (Nasdaq: TARS) announced an oversubscribed USD 125 million private investment in public equity (PIPE)...
Dispatch advances synthetic-antigen CAR T platform into first-in-human testing
Dispatch Bio has dosed the first patient in a Phase I study of DISP-10 immunotherapy, a combination approach pairing a tumor-specific virus with an approved...
Vistagen reports exploratory Phase II miss for social anxiety drug candidate
South San Francisco-based Vistagen Therapeutics (Nasdaq: VTGN) reported topline results on August 6 from an exploratory Phase II study of fasedienol nasal...
Edding Genor tries trispecific PD-1/CTLA-4/VEGF antibody against breast cancer
Hong Kong-listed Edding Genor Group Holdings Limited (HKEX: 06998) announced on August 6 that the first subject has been dosed in the Phase Ib/II clinical...
ReCode expands cystic fibrosis gene editing push with new CF Foundation backing and unnamed partner
Mountain View, California-based ReCode Therapeutics announced a research collaboration with an undisclosed gene editing company to develop a CFTR-correcting...
Biogen closes deal for USD 1b buyout of RayThera
Biogen (Nasdaq: BIIB) has completed its acquisition of RayThera Inc., a San Diego-based small-molecule immunology company, for a total potential...
EU clears label expansion for Bavarian Nordic's Mpox vaccine to children as young as two
The European Commission has approved a label extension for Imvanex (MVA-BN), Denmark-based Bavarian Nordic's (OMX: BAVA) non-replicating smallpox and mpox...
Replimune secures accelerated approval for oncolytic viral therapy Tudriqev
The US FDA has granted accelerated approval to Tudriqev (vusolimogene oderparepvec-wtpg), a genetically modified oncolytic viral therapy developed by...
Latigo raises USD 345.6m in upsized IPO backed by Nav1.8 Phase II data
Latigo Biotherapeutics, Inc. (Nasdaq: LTGO), a Thousand Oaks, California-based clinical-stage biopharmaceutical company whose lead Nav1.8 inhibitor recently...
Transcenta sells CDMO assets to WuXi Bio to focus on drug pipeline
Transcenta Holding Limited (HKEX: 6628) has agreed to sell its Hangzhou contract development and manufacturing organization assets to WuXi Biologics...
Washington University wins NIA grant to study immune clearance in Alzheimer's disease
Note: The orglookupsummary returned a mismatched result (Western Washington University) that does not correspond to the funded institution, Washington...
University of Colorado renews work on CAR-phagocyte pediatric brain cancer therapy
The University of Colorado Cancer Center has received a USD 1.28 million NIH R01 renewal from the National Cancer Institute to develop chimeric antigen...
The AllSci Brief
Free, systematic R&D and deal news. Daily.